

Special Issue

Radiotherapy in Gynecological Cancer: State of the Art

Message from the Guest Editors

This Special Issue of *Cancers* considers the quick evolution of radiation oncology in the gynaecological tumour sites of endometrial, cervical, vaginal and vulvar cancers. Considering the variety of advances achieved in the last decade, radiotherapy in gynaecological cancer has become increasingly well established and there has been an increase in cancer treatment results. At present, new indications and new techniques to be employed in this scenario include intensity-modulated radiotherapy, image-guided external beam irradiation, image-guided brachytherapy, stereotactic body radiation and intraoperative radiotherapy between others. Recently, tumour markers have been related to radiotherapy indications, leading omics-based and other adjuvant treatments to now be in the pipeline. Artificial intelligence is currently being developed for future use in this field. This is a promising Special Issue that aims to establish the state of the art in the radiotherapy of gynaecological cancers via reviews or research articles developed by radiation oncologists, medical oncologists and medical physicists, with a view into the future.

Guest Editors

Dr. Àngeles Rovirosa
Dr. Gabriella Macchia
Dr. Luca Tagliaferri

Deadline for manuscript submissions

closed (20 April 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/184046

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)